EvaluatePharma’s 10 best-selling drugs in 2026 and their expected global sales:
- Keytruda (Merck) — $24.9 billion
- Opdivo (Bristol Myers Squibb) — $12.7 billion
- Eliquis (Bristol Myers Squibb) — $12.6 billion
- Biktarvy (Gilead) — $11.7 billion
- Imbruvica (AbbVie + Johnson & Johnson) — $10.7 billion
- Ibrance (Pfizer) — $9.7 billion
- Tagrisso (AstraZeneca) — $9.5 billion
- Dupixent (Sanofi) — $9.4 billion
- Trikafta (Vertex Pharmaceuticals) —$8.7 billion
- Ozempic (Novo Nordisk) — $8.3 billion
More articles on pharmacy:
Walgreens CEO steps down
AstraZeneca, Daiichi Sankyo partner in $6B cancer drug deal
Trump signs 4 executive orders targeting drug prices: 6 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
